$250 Million

Dermira

Convertible Debt

Bookrunner, May 2017

Dermira is a biopharmaceutical company that identifies, develops, and commercializes novel therapies to treat dermatologic diseases with significant unmet need. In June 2018, the Company’s lead product candidate, Qbrexza, received FDA approval for the treatment of Primary Axillary Hyperhidrosis., a chronic skin condition affecting approximately 15 million people in the United States. The Company is also developing lebrikizumab, a humanized monoclonal antibody for the treatment of atopic dermatitis, and recently announced positive results from its Phase 2b dose-ranging study. Lebrikizumab is designed to specifically block the action of interleukin-13, or IL-13, a cytokine that is a central pathogenic mediator in atopic dermatitis, a severe form of eczema affecting approximately 33 million people in the United States.

More Like This

Jan 2021
$69 Million

Convertible Notes Restructuring

Exclusive Financial Advisor

View Details >
Nov 2020
$197 Million
Tilray Logo

Convertible Notes Exchange

Exclusive Financial Advisor

View Details >
Nov 2020
$1.15 Billion

Convertible Debt

Co-Manager

View Details >